Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
about
Advanced gastric cancer: Current treatment landscape and future perspectivesClinical modalities for management of gastric cancer hepatic metastasisSecond-line treatment of metastatic gastric cancer: Current options and future directionsThe efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationLow-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysisEfficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients.Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.Lauren classification and individualized chemotherapy in gastric cancer.A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy.A case report of curative distal gastrectomy for stage IV gastric cancer after chemoradiotherapy in a patient with a gastrojejunal gastric bypass.Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.Chemotherapy for advanced gastric cancer.Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.Japanese gastric cancer treatment guidelines 2014 (ver. 4).Long-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case report.5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).Systemic chemotherapy as a main strategy for liver metastases from gastric cancer.Case of pseudo-Meigs' syndrome caused by gastric cancer-related metastatic ovarian tumor with prolonged survival.The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios.Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.The long-term survival of stage IV gastric cancer patients with conversion therapy.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322.Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer.A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.
P2860
Q26764934-41B5F239-236F-47C9-BBFC-917D1B71318DQ26765314-37E491FA-5AF6-4F53-BE0B-B67F6B982999Q26778027-D1BFF27E-7FAA-4D72-B567-8568692228D0Q27318805-A3F6A687-B978-4F87-B802-E99A87694984Q28084888-4366838A-81FE-4072-BE4D-3FBDE7049A2DQ33425150-F96043A8-7530-42F6-972B-44384A821C6AQ33433129-53ADDE8D-0EDB-4FE1-9F5D-0130A00312DAQ33889328-00E9937D-A4E5-414E-BFED-5D357B62FB1CQ33902814-EA04D850-3322-4E20-A654-E25ED78EF8EAQ35996020-DDF86C74-8AAC-4D6B-AFCE-CDCD77E5B9EAQ36396339-5265071E-21FB-48B0-8F0C-DF151F535848Q36824887-EA4CE8BF-D1DB-4260-859B-7423F280C201Q37004336-7AA2BDE9-2908-40B7-9E06-7987B892A61AQ37410030-492C518F-C3C7-41B1-899A-18C2970A5043Q37701789-7683CDDF-E64C-416B-9BFB-03835A782999Q38497265-8F900C09-2F93-41F1-A86D-5D1EF7959434Q38604012-15B52C6A-27BD-4BC9-BA96-7B0055A3EB25Q38647893-8183C123-AF0D-4B7A-9A7C-A9DFB5C472F1Q38687532-5BE93528-DBC1-489D-8262-AF0305679688Q38800565-AEC6EC44-1FC4-4735-AD99-8BF790ABCC73Q38941416-DA08AD29-13DB-49AB-9398-76B291EA782AQ39656427-5195D3A5-F842-4B06-BF44-15306CF0AA51Q41423472-F8234067-8371-4DA5-BABA-011CF6AA867DQ41617745-5268B7E9-3FF0-4A85-A13E-DF354C29D111Q41643156-F058DDFC-A50E-4D8E-AE9B-3E86663DDB04Q41644087-AD372BC2-3C51-4006-B2EE-73C194F79102Q42135178-6E5041D4-9CCD-4FDC-9118-61B68D238E16Q46207048-577E0496-E6B7-4E56-A1EA-07D2BBCB95E4Q47178340-862E631D-E164-4368-B5B8-821A66BA8C11Q47285124-BA270802-DD51-42C5-B699-CD9B53172B92Q47345549-D8DE371D-B67E-4882-995D-224D63142E6DQ47402625-9477D923-1DE1-4C74-9EC8-74ED24FAD7DDQ48052472-A470A2DD-690B-4918-A2BB-17A2F402153DQ48112488-616757E8-B700-46A6-B4A0-0003BDA65C63Q48194003-30A2C3CA-ECA2-456E-AA3E-9176859ACC15Q48327644-51B10A11-2CCA-49C1-955C-CF3CC0AF14A2Q49194716-85D6F8F2-5F5A-4EB2-B6DF-B850F65C3901Q50650462-4BD0DFD6-F20C-481F-B1E3-F18A3DA96CB1Q53458026-C44EA52B-59FC-4A01-BEBD-020AAEFD5AB1Q53560105-33154F51-20B1-4B7E-8ABF-31DBFBCF6D84
P2860
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Addition of docetaxel to S-1 w ...... r: a randomized study (START).
@en
Addition of docetaxel to S-1 w ...... ric cancer: a randomized study
@nl
type
label
Addition of docetaxel to S-1 w ...... r: a randomized study (START).
@en
Addition of docetaxel to S-1 w ...... ric cancer: a randomized study
@nl
prefLabel
Addition of docetaxel to S-1 w ...... r: a randomized study (START).
@en
Addition of docetaxel to S-1 w ...... ric cancer: a randomized study
@nl
P2093
P2860
P1476
Addition of docetaxel to S-1 w ...... r: a randomized study (START).
@en
P2093
Akihito Tsuji
Akinori Takagane
Hiroshi Imamura
Hisashi Hosaka
Hoon Kyo Kim
JACCRO and KCSG Study Group
Kazuaki Tanabe
Kazuhiro Yoshida
Kyung Hee Lee
Mariko Ogura
P2860
P2888
P304
P356
10.1007/S00432-013-1563-5
P577
2013-12-24T00:00:00Z